Pharmaceutical Industries Ltd.
Your browser does not support iframes.
See Teva's sites around the world
Japan & S. Korea
Bosnia & Herzegovina
Want to find out more about Teva's locations and phone numbers?
Visit Teva Worldwide
Board of Directors
2016 Annual Report on Form 20-F
Notice of Annual Meeting of Shareholders 2017 – Proxy Statement
Over the Counter (OTC)
Central Nervous System (CNS)
Teva at IATI BIOMED 2015
Leading the Fight for Cures
National Network of Excellence
Position on Antimicrobial Resistance (AMR)
2016 Social Impact Report
Previous CSR Reports
Supplier Code of Conduct & Information for Our Suppliers
Global Patient Organization and Advocacy Disclosure
Teva Fact Sheet
Four New Independent Directors Join the Teva Board
Webcasts and Presentations
Grow with the Best
Our Guiding Values
Grow with the Best
Go to Parent
New Therapeutic Entities (NTEs)
In our generics R&D, there is much more to generics than meets the eye. We bring creativity, innovative thinking, and the ability to analyze, formulate and execute in a timely and effective manner. This is particularly true in the area of complex, hard to develop generics, where we deliver a real competitive edge.
Share on Facebook
Share on LinkedIn
Generics. More than Meets the Eye
Our generics R&D is closely integrated with our extensive clinical expertise in developing specialty and OTC products. This makes us the only global pharmaceutical company that has an integrated generic and specialty (branded) R&D capability.
With generics R&D and specialty R&D working hand-in-hand, this unique combination of strengths, capabilities and skills enables new ideas and improved innovation.
Proud of Our Heritage, Inspired by New Possibilities
Great medicines start with great minds. Our R&D group maintains a mindset of exceptional professionalism, matched by speed, flexibility and a desire for value creation for patients, healthcare providers and customers worldwide. Our strengths in generics R&D are directed at fostering discovery and innovation.
Our generics R&D capabilities have expanded beyond tablets, capsules, liquids, ointments and creams to a broad range of dosage forms and delivery systems. These include sterile devices, modified release parenteral injectables, transdermal patches and films, and nasal suspensions. Our generics R&D group continues to develop an array of special delivery technologies ranging from extended-release to drug device combinations.
More Value for More People Around the World
We’re working around the world, and around the clock to deliver affordable medicines in a multitude of therapeutic areas. Our generics R&D activities are carried out in development centers in the United States, Europe, Latin America, Israel, Japan and India. We are focused on the development of complex, difficult to produce, high-value treatment options to address the unmet needs of patients and improve health outcomes.
Did You Know?
We are the leading generics company in the world:
• Across the world approximately 200 million patients per year are helped by our generic medicines
• Approximately 1 out of every 8 US pharmaceutical prescriptions is filled with a Teva product*
• We are the largest single provider of medicines to the UK’s NHS, saving £2.8 billion from the NHS drug bill.
• Teva markets over 1,000 generic molecules and has hundreds of molecules in development
• 73 billion pills a year are manufactured by Teva for patients across the world
* IMS Health NPA MAT June 2014.
You May Also Like...
Teva Prize for Poetry
National Multiple Sclerosis Society Honors Teva
Teva Canada & TO-the-World Participate in Ugandan Mission
Grow with the Best